A novel RUNX2 missense mutation predicted to disrupt DNA binding causes cleidocranial dysplasia in a large Chinese family with hyperplastic nails

Shaohua Tang¹, Qiyu Xu¹, Xueqin Xu¹, Jicheng Du¹, Xuemei Yang¹, Yusheng Jiang¹, Xiaoqin Wang¹, Nancy Speck² and Taosheng Huang*³

Address: ¹The prenatal diagnostic Center of Wenzhou City, Department of genetics of Wenzhou No2 Hospital, Wenzhou, China, ²Department of Biochemistry, Dartmouth Medical School, Hanover, New Hampshire, USA and ³Department of Pediatrics, Division of Human Genetics & Metabolism, Department of Developmental and Cell Biology, Department of Pathology, University of California, Irvine, CA, USA

Email: Shaohua Tang - tsh006@163.com; Qiyu Xu - 0105062@sohu.com; Xueqin Xu - xxq@yilian.com.cn; Jicheng Du - wzDuJicheng@163.com; Xuemei Yang - yxmcqzd@126.com; Yusheng Jiang - yusheng0104@hotmail.com; Xiaoqin Wang - wxqwz@126.com; Nancy Speck - Nancy.Speck@Dartmouth.edu; Taosheng Huang* - huangts@uci.edu

* Corresponding author

Abstract

Background: Cleidocranial dysplasia (CCD) is a dominantly inherited disease characterized by hypoplastic or absent clavicles, large fontanels, dental dysplasia, and delayed skeletal development. The purpose of this study is to investigate the genetic basis of Chinese family with CCD.

Methods: Here, a large Chinese family with CCD and hyperplastic nails was recruited. The clinical features displayed a significant intrafamilial variation. We sequenced the coding region of the RUNX2 gene for the mutation and phenotype analysis.

Results: The family carries a c.T407C (p.L136P) mutation in the DNA- and CBFβ-binding Runt domain of RUNX2. Based on the crystal structure, we predict this novel missense mutation is likely to disrupt DNA binding by RUNX2, and at least locally affect the Runt domain structure.

Conclusion: A novel missense mutation was identified in a large Chinese family with CCD with hyperplastic nails. This report further extends the mutation spectrum and clinical features of CCD. The identification of this mutation will facilitate prenatal diagnosis and preimplantation genetic diagnosis.

Background

Cleidocranial dysplasia [CCD, Min 119600] is a skeletal dysplastic disorder. Clinical features include delayed closure of skull sutures, hypoplastic or aplastic clavicles, and dental anomalies [1]. Patients often present with wide-open fontanels and middle face dysplasia, such as depressed nasal bridges. Clavicular hypoplasia can cause narrow, sloping shoulders that are often opposed at the mid line. Other clinical features include brachydactyly, tapering fingers, and short, broad thumbs and toes. Dental malformations include delayed eruption of secondary dentition and failure to shed primary teeth, which results in supernumerary teeth with dental crowding and malocclusion [2,3].
A variety of mutations in RUNX2 cause CCD [4-11], but no clear genotype-phenotype correlation has been established in CCD patients [8]. RUNX2 is an osteoblast-specific transcription factor that is a member of the core binding factor (CBF) [12]. RUNX2 interacts with a non DNA-binding CBFβ subunit and the resulting complex binds to cis-acting elements in the promoters of genes required for skeletal formation such as osteocalcin [13]. The RUNX2-CBFβ complex serves as a master regulator of osteoblast differentiation and a scaffold that controls the assembly of transcription factors regulating skeletal gene expression [14]. In addition to osteocalcin, RUNX2 regulates vascular endothelial growth factor (VEGF) [15], COL10A1, and matrix metalloproteinase 13 (MMP13) [16]. COL10A1 is crucial for chondrocyte hypertrophy. VEGF and MMP13 are critical for hypertrophic chondrocytes, and mutations in RUNX2 result in a markedly diminished hypertrophic zone in long bone cartilage [17]. Additionally, RUNX2 and phosphatidylinositol 3-kinase (PI3K) regulate osteoblast and chondrocyte differentiation and migration in a mutually dependent manner [18]. Signal transducer and activator of transcription 1 (STAT1) also interacts with RUNX2 and attenuates its transcriptional activity through cytoplasmic sequestration [19].

It has been shown that overexpression of RUNX2 results in growth arrest through p27 (KIP1)-induced inhibition of the s-phase cyclin complex, followed by dephosphorylation of the RB1 protein [20]. Since osteoblast proliferation and differentiation are inversely correlated, RUNX2 inhibits osteoblast proliferation. Here, we report a large Chinese family with CCD. We predict that a novel mutation of RUNX2 disrupts the protein-DNA interaction.

### Methods

**Patients**

The pedigree is shown in Figure 1. The proband (II-7) is a 34-year-old G3P1 female. She received medical attention for her polyhydramnia and short stature. Upon physical examination, her height was 141.5 cm, weight 60 kg, and her arm span was 146.5 cm. She had an asymmetric face, a bossing of the forehead, hypertelorism, a depressed nasal bridge, malocclusion of teeth, a prominent lower jaw, sloping shoulders, and hyperplastic fingernails and toenails. X-ray analysis showed wormian bones and poor pneumatization of the sinuses (Figure 2A); her right cuspid tooth had not erupted and was hypoplastic. A chest x-ray revealed a cone-shaped chest, high scapular bones, aplasia of lateral and middle third of the clavicle, mild scoliosis between T6 and T10 (Figure 2B), and mild dislocation of vertebrae between L5-S1 (Figure 2C), a widening sacroiliac joint, a wide pubic symphysis, hypoplastic pubic bones (Figure 2D), normal hips. The knee and hand x-rays were normal. The family history shows that there are 11 affected individuals (6 males, 5 females) (Figure 1) from a total of 28 individuals in the family. All affected individuals have short stature, but other clinical features are very variable (Table 1). For example, several affected individuals have a normal clavicle. The cranial facial features ranged from macrocephaly to severely depressed anterior fontanelles. The most striking feature of this family is that all affected individuals have hyperplastic nails (Figure 3) which is not seen in unaffected family members, and has not been previously described in CCD patients.

**Genetic analysis**

Informed consent was obtained in accordance with a protocol approved by the Wenzhou 2nd People Hospital Human Subject Review Board. 3 ml of blood was drawn and stored in EDTA anticoagulation tubes. Genomic DNA was purified with a genomic DNA purification kit (version 3.0, Baosheng Company, Daling, China). Genomic DNA was PCR-amplified as previously described. Eight sets of exon-specific primers were used to amplify the RUNX2 coding region [6]. The primers correspond to intron sequences, typically 30 to 50 bp away from the exon-intron boundary.

PCR was carried out using a PCR kit, following the manufacturer’s instructions (Baosheng Company, Daling, China). The genomic DNA was first denatured at 94 °C for 3 minutes, followed by 32 cycles of 94°C for 20 seconds, 50°C to 60°C for 30 seconds, and 72°C for 30 seconds.

### Table 1: Clinical Manifestation of Family with CCD

| Patient | Sex | Age | Height (cm) | Cranial | Shoulders | Clavicle | Nails | Other |
|---------|-----|-----|-------------|---------|-----------|---------|-------|-------|
| I1      | F   | 76  | very short  | frontal bossing | sloping, bilateral | absence of lateral 1/3, bilateral | elevated nail bed | elevated nail bed |
| II1     | F   | 52  | 140.0       | increased suture space | severe sloping, bilateral | absence of lateral 1/3, bilateral | elevated nail bed | elevated nail bed |
| II3     | M   | 49  | 150.5       | depressed anterior fontanelles | severe sloping, bilateral | absence of lateral 1/3, right | elevated nail bed | elevated nail bed |
| II6     | M   | 40  | 152.0       | frontal bossing | mild sloping, bilateral | absence of lateral 1/3, right | elevated nail bed | normal ALP |
| II7     | F   | 34  | 141.5       | frontal bossing | mild sloping, bilateral | absence of lateral 1/3, bilateral | elevated nail bed | elevated nail bed |
| III2    | M   | 33  | 155.0       | increased suture space | severe sloping, bilateral | absence of lateral 1/3, bilateral | elevated nail bed | elevated nail bed |
| III4    | F   | 26  | 134.5       | severe depressed anterior fontanelles | Sloping, bilateral | elevated nail bed | normal ALP | normal ALP |
| III12   | F   | 12  | 120.0       | frontal bossing | Sloping, bilateral | normal | elevated nail bed | elevated nail bed |
| III14   | M   | 3   | 80.0        | frontal bossing | increased mobility, Bilateral | normal | elevated nail bed | elevated nail bed |
| IV2     | M   | 4   | 90.0        | macrocephaly | increased mobility, Bilateral | absence of lateral 1/3, right | elevated nail bed | elevated nail bed |
| IV3     | M   | 2   | 83.5        | macrocephaly | increased mobility, Bilateral | elevated nail bed | elevated nail bed | elevated nail bed |
The PCR products were extended at 72°C for 5 minutes. The products were gel-purified with an agarose gel DNA purification kit, version 2.0 (Baosheng Company, Daling, China), and the purified PCR products sequenced using the forward and reverse primers. The sequences were analyzed with DNAStar.

Results
We detected a single base-pair variant in exon 1 that was verified by sequencing both strands (Figure 4). This variant in the cDNA at position 407 results in the substitution of leucine 136 with proline (Left panel). It co-segregates with affected individuals of the family. There is no such a sequence variant at that position in unaffected individuals (Right panel). More than 200 population-matched chromosomes were sequenced and no sequence variations were detected, suggesting that the sequence aberration is
pathogenic. A leucine at that position is conserved in the Runt domain proteins of all vertebrates, suggesting it is functionally important (Figure 5A). The analogous residue in RUNX1 is L85, which in the crystal structures of the highly conserved RUNX1 Runt domain-CBF β-DNA ternary complex is located in the βA'-B loop [21]. Two adjacent residues in the βA'-B loop, R131 and K134 are predicted to directly contact the DNA based on the RUNX1 structure (Figure 5B). The L136 side chain is oriented away from the DNA interface. Substitution of L136 with proline is predicted to alter the structure of the DNA-binding βA'-B loop, and thereby impair DNA binding by RUNX2. Several mutations at the DNA binding interface in RUNX1 were shown to also affect binding of CBF β to the opposite side of the Runt domain because of their overall effect on the Runt domain structure [22] (Matheny CJ et al, unpublished data). One of these mutations was R80C, which is also located in the RUNX1 βA'-B loop (corresponding to R131 in RUNX2). Therefore, it is possible that the L136P mutation in RUNX2 would also affect CBF β binding, but this was not directly tested.

**Discussion**

Thus far, more than 70 mutations have been identified in the RUNX2 gene. The mutations are clustered in the Runt domain but occur throughout the RUNX2 protein. RUNX2 binds to DNA in a sequence-specific manner and CBF β enhances its DNA binding affinity. Here, we identified a novel missense mutation in the Runt domain in a large Chinese family. Clinically, all affected individuals have hyperplastic nails. We show for the first time an unusual phenotype, hyperplastic nails, the molecular basis of which is unknown. This additional phenotype is most likely caused by RUNX2 mutation. However, we cannot rule out the possibility that another genetic alternation is co-segregated with the RUNX2 gene and associated with this phenotype. The most likely mechanism by which the L136P mutation affects RUNX2 function is through impaired DNA binding caused by structural alterations in the DNA-binding βA'-B loop. The identification of the L136P mutation in this family further expands the clinical phenotypes and mutation spectrum, and will contribute to prenatal molecular diagnosis and preimplantation genetic diagnoses.

Thus far, genotype-phenotype correlations have not been established for the different RUNX2 mutations found in CCD, although Zhou et al. [11] suggested that a T200A mutation found in a family with mild CCD might be a hypomorphic mutation. The hypomorphic nature of the T200A mutation was recently confirmed in mice [11] (Matheny CJ et al, unpublished data). There is variable expressivity of RUNX2 CCD mutations. For example, in one Italian family with a RUNX2 mutation, the reported clinical features ranged from minimal or absent clavicle to the presence of hypoplastic clavicles and delayed closure of the anterior fontanel in addition to classic craniofacial features. The family we describe here also displays significant intrafamilial phenotypic variation, indicating that
there are modifying alleles at other loci. It is uncommon for CCD patients to display clinical features other than skeletal abnormalities. Two Italian CCD patients were reported to exhibit shoulder muscle abnormalities [23]. Quack et al. reported that an R225Q mutation affects nuclear RUNX2 accumulation and results exclusively in dental phenotypes. One patient with mutations resulting in an amino acid substitution at position 702 in sequences C-terminal to the Runt domain had osteoporosis, suggesting that RUNX2 not only functions in skeletal development, but also in maintaining adult bone density [6]. Extensive mutagenesis experiments have shown that many RUNX2 mutations impair DNA binding, while others affect CBFAβ binding or the Runt domain structure [9,11,21,24-29] (Matheny CJ et al., unpublished data).

Conclusion
L136P is a novel mutation that most likely interferes with DNA binding by RUNX2 and would result in a nonfunctional or strongly hypomorphic allele.

Abbreviations
CCD, Cleidocranial dysplasia; CBF, core binding family; VEGF, vascular endothelial growth factor; MMP13, matrix metalloproteinase 13; PI3K, phosphatidylinositol 3-kinase; STAT1, signal transducer and activator of transcription 1.

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
ST conceived of the study, carried out the molecular genetic studies and drafted the manuscript. JD participated in the experimental design, coordinate the molecular genetic studies. XX participated in the genetic studies and drafted the manuscript. QX carried out the experimental design, coordinate the molecular genetic studies. YY participated in the clinical data collection and X-ray analysis. XY participated in the clinical data collection. YJ participated in the sequence analysis. XW participated in design and coordination. NS participated in 3-D modeling and manuscript preparation. TH participated in the experimental design, coordinate the project and manuscript preparation.

Acknowledgements
We thank the patients for participating in our study and the physicians for referring the patients to us. Written consent for publication was obtained from the patient or their relative. This project is partially supported by the prenatal diagnostic Center of Wenzhou City. We would also like to thank Professor Pamela Flodman for critical reading this manuscript. TH is partially supported by an NIH clinical associate physician award, and NAS by RO1CA58343.

References
1. Jackson WP: The generalized developmental osseous dystrophies. 8. Osteo-dental dysplasia (cleidocranial dysostosis); general summary. S Afr Med J 1951, 25(27):475-477.
2. Cooper SC, Flaitz CM, Johnston DA, Lee B, Hecht JT: A natural history of cleidocranial dysplasia. Am J Med Genet 2001, 104(1):1-6.
3. Golan I, Baumert U, Prager R, Aknin J, Roedde J, Müssig D: [Interm. intrafamilial expression of cleidocranial dysostosis]. Orthod Fr 2003, 74(1):7-13.
4. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Allbright S, Lindhout D, Cole WG, Henn W, Knoll JH et al.: Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997, 89(5):773-779.
5. Quack I, Vonderstrass B, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR et al.: Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997, 89(5):765-771.
6. Quack I, Vonderstrass B, Stock M, Aylsworth AS, Becker A, Brueton L, Lee PJ, Majewski F, Mulliken JB, Suri M, et al.: Mutation analysis of core binding factor A1 in patients with cleidocranial dysplasia. Am J Hum Genet 1999, 65(5):1268-1278.
7. Bergwitz C, Prochnau A, Mayer B, Kramer FJ, Rittierodt M, Benten HL, Haussmen JE, Brabant G: Identification of novel CBFA1/RUNX2 mutations causing cleidocranial dysplasia. J Inherit Metab Dis 2001, 24(6):648-656.
8. Otto F, Kanegane H, Mundlos S: Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Hum Mutat 2002, 19(3):209-216.
9. Lee B, Thirunavukkarasu K, Zhou L, Pastore L, Baldini A, Hecht J, Geoffroy V, Ducy P, Karsenty G: Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet 1997, 16(3):307-310.
10. Zhang YW, Yasui N, Kakazu N, Abe T, Takada K, Imi S, Sato M, Nomura S, Ochi T, Okuzumi S, et al.: PEBP2alphaA/CBFA1 mutations in Japanese cleidocranial dysplasia patients. Gene 2000, 244(1-2):21-28.
11. Zhou G, Chen Y, Zhou L, Thirunavukkarasu K, Hecht J, Chiatay D, Gelb BD, Pirinen S, Berry SA, Greenberg CR et al.: CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia. Hum Mol Genet 1999, 8(12):2311-2316.
12. Geoffroy V, Corral DA, Zhou L, Lee B, Karsenty G: Genomic organization, expression of the human CBFA1 gene, and evidence for an alternative splicing event affecting protein function. Mamm Genome 1998, 9(1):34-57.
13. Gutierrez S, Javed A, Tennant DK, van Rees M, Montecino M, Stein GS, Stein JL, Lian JB: CCAAT/enhancer-binding proteins (C/EBP) beta and delta activate osteocalcin gene transcription and synergize with Runx2 at the C/EBP element to regulate bone-specific expression. J Biol Chem 2002, 277(2):1316-1323.
14. Stein GS, Lian JB, van Wijnen AJ, Stein JL, Lian JB, Montecino M, Javed A, Zaidi SK, Young DW, Choi JY, Pockwinse SM: Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 2004, 23(24):4315-4329.
15. Selzer E, Glotzer D, Hartmann C, Thomas D, Fukai N, Soker S, Olsen BR: Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. Mech Dev 2001, 106(1-2):97-106.
16. Enomoto H, Enomoto-Iwamoto M, Iwamoto M, Nomura S, Higashimori Y, Komura Y, Kishimoto T, Komori T: Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol 2004, 166(1):85-95.
17. Fujita T, Azuma Y, Fukuyama R, Hattori Y, Yoshida C, Koida M, Ogitana K, Komori T: Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol 2004, 166(1):85-95.
18. Kim S, Koga T, Yukioka T, Ichihara M, Yamada J, Kishimoto T, Komori T: Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol 2004, 166(1):85-95.
19. Fujita T, Azuma Y, Fukuyama R, Hattori Y, Yoshida C, Koida M, Ogitana K, Komori T: Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol 2004, 166(1):85-95.
20. Thomas DM, Johnson SA, Sims NA, Trivett MK, Slavin JL, Rubin BP, Waring P, McArthur GA, Wallkey CR, Holloway AJ et al.: Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 2004, 167(5):925-934.
21. Zhang L, Li Z, Yan J, Pradhan P, Corpora T, Cheney MD, Bravo J, Warren AJ, Bushweller JH, Speck NA: Mutagenesis of the Runt domain defines two energetic hot spots for heterodimerization with the core binding factor beta subunit. J Biol Chem 2003, 278(35):33097-33104.

22. Li Z, Yan J, Matheny CJ, Corpora T, Bravo J, Warren AJ, Bushweller JH, Speck NA: Energetic contribution of residues in the RunxI Runt domain to DNA binding. J Biol Chem 2003, 278(35):33088-33096.

23. Tessa A, Salvi S, Casali C, Garavelli L, Digilio MC, Dotti MT, Di Gian-domenico S, Valoppi M, Grieco GS, Comanducci G, et al.: Six novel mutations of the RUNX2 gene in Italian patients with cleido-cranial dysplasia. Hum Mutat 2003, 22(1):104.

24. Harada H, Harada Y, Tanaka H, Kimura A, Inaba T: Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 2003, 101(2):673-680.

25. Michaud J, Wu F, Osato M, Cortes GM, Yanagida M, Asou N, Shigesada K, Ito Y, BensonKF, Raskind WH, et al.: In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood 2002, 99(4):1364-1372.

26. Nagata T, Werner MH: Functional mutagenesis of AML1/ RUNX1 and PEBP2 beta/ CBF beta define distinct, non-overlapping sites for DNA recognition and heterodimerization by the Runt domain. J Mol Biol 2001, 308(2):191-203.

27. Osato M, Asou N, Abdalla E, Hoshino K, Yamashita H, Okubo T, Suzushima H, Takatsuki K, Kanno T, Shigesada K, et al.: Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alpha beta gene associated with myeloblastic leukemias. Blood 1999, 93(6):1817-1824.

28. Tahirov TH, Inoue-Bungo T, Morii H, Fujikawa A, Sasaki M, Kimura K, Shiihira M, Sato K, Kumasaka T, Yamamoto M, et al.: Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell 2001, 104(5):755-767.

29. Yoshida T, Kanegane H, Osato M, Yanagida M, Miyawaki T, Ito Y, Shigesada K: Functional analysis of RUNX2 mutations in Japanese patients with cleidocranial dysplasia demonstrates novel genotype-phenotype correlations. Am J Hum Genet 2002, 71(4):724-738.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2350/8/82/prepub